Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03469947 | California Prehospital and In Hospital Antifibrinolytic Therapy Via TXA | PHASE3 | COMPLETED | 200 | — | — | Mar 1, 2015 | Jul 29, 2024 | Jul 30, 2024 | - | — |
Mortality at 24 hours
Mortality at 48 hours
Mortality at 28 days
| Arm | Type | Description |
|---|---|---|
| Prehospital Tranexamic Acid | EXPERIMENTAL | 1 gram of Tranexamic Acid will be given during medical transport |
| Matched Controls | NO_INTERVENTION | Retrospective matched controls |
| Name | Type | Description |
|---|---|---|
| Tranexamic Acid | DRUG | 1 gram of prehospital Tranexamic Acid |
Inclusion Criteria: * Blunt or penetrating trauma with signs and symptoms of hemorrhagic shock * Systolic blood pressure less than 90 mmHg at scene of injury, during air and/or ground medical transport, or on arrival to designated trauma centers * Any sustained blunt or penetrating injury within 3 ...